Thinking of joining a study?

Register your interest

NCT05141435 | Recruiting | to Test the Hypothesis That NHFOV is More Effective Than nCPAP in the Treatment of Respiratory Distress Syndrome (RDS) in Verypreterm Neonates


NHFOV as Primary Support in Very Preterm Infants With RDS
Sponsor:

Jiulongpo No.1 People's Hospital

Information provided by (Responsible Party):

xingwangzhu

Brief Summary:

This will be a prospective, multi-center, two-arms,parallel, randomized, controlled trial with a superiority design,conducted in China. The investigators conduct this multi-centre, randomized, controlled trial to test the hypothesis that NHFOV is more effective than nCPAP in the treatment of respiratory distress syndrome (RDS) in infants with a gestational age of less than 28 weeks when used as a primary noninvasive ventilation (NIV) mode.

Condition or disease

to Test the Hypothesis That NHFOV is More Effective Than nCPAP in the Treatment of Respiratory Distress Syndrome (RDS) in Verypreterm Neonates

Intervention/treatment

infants receive primary non-invasive respiratory support by mean of nCPAP

infants receive primary non-invasive respiratory support by mean of NHFOV

Phase

Not Applicable

Detailed Description:

Preterm infants are eligible to the study if they they match the following inclusion criteria: (1) Gestational age between 240/7 and 286/7 weeks; (2) diagnosis of RDS. The diagnosis of RDS will be based on clinical manifestations (tachypnea, nasal flaring and or grunting) and a fraction of inspired oxygen (FiO2) greater than 0.25 for target saturation of peripheral oxygen (SpO2) 89% to 94%;; (3) Age less than 2 hours; (4)Informed parental consent has been obtained. Neonates will be randomized and assigned either to nCPAP or NHFOV arms with a 1:1ratio, when patients fulfill all inclusion criteria. Randomization cannot be done earlier. Simple randomization will be done according to a computer-generated random number table and will be posted in a specific secured website 24/7 available. Twins will be allocated in the same treatment group. Infants randomized to one arm cannot crossover to the other or vice- versa during the study. For all the groups, if the fraction of inspired oxygen (FiO2) requirement is persistently higher than 0.30 per target SpO2 89-94% after starting the respiratory support, newborns receive Surfactant by "LISA" technique, administration of surfactant (Curosurf,Chiesi Pharmaceutics, Parma, Italy) 200 mg/kg. After the administration of surfactant, if FiO2 requirement is persistently >0.4 to keep SpO2 89-94% or severe apnea episodes are present (defined as recurrent apnea with >3 episodes/h associated with heart rate <100/min or a single episode of apnea requiring bag and mask ventilation within a 24-hour period ) or at the blood gas (arterial or free-flowing capillary blood) PaCO2>60 mmHg and potential of hydrogen (pH)<7.20 obtained at least 1 hour after commencement of the assigned treatment, newborns are intubated and mechanically ventilated. For all the newborns enrolled in the study, arterial or free-flowing capillary blood gas is checked every 6-12 hours, a cerebral and cardiac ultrasound screening is performed within 24 hrs. Further controls follow the routine of the ward.}}

Study Type : Interventional
Estimated Enrollment : 340 participants
Masking : None (Open Label)
Primary Purpose : Treatment
Official Title : NHFOV vs nCPAP in Very Preterm Infants With Respiratory Distress Syndrome: A Multi-center, Prospective, Randomized, Controlled Clinical Superior Trial
Actual Study Start Date : August 1, 2022
Estimated Primary Completion Date : February 15, 2023
Estimated Study Completion Date : April 15, 2023
Arm Intervention/treatment

Active Comparator: NCPAP

Procedure: infants receive primary non-invasive respiratory support by mean of nCPAP

Procedure: infants receive primary non-invasive respiratory support by mean of NHFOV

Active Comparator: NHFOV

Procedure: infants receive primary non-invasive respiratory support by mean of nCPAP

Procedure: infants receive primary non-invasive respiratory support by mean of NHFOV

Ages Eligible for Study: 0 Hours to 2 Hours
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Criteria
Inclusion Criteria
  • (1) Gestational age between 240/7 and 286/7 weeks; (2) diagnosis of RDS. The diagnosis of RDS will be based on clinical manifestations (tachypnea, nasal flaring and or grunting) and a fraction of inspired oxygen (FiO2) greater than 0.25 for target saturation of peripheral oxygen (SpO2) 89% to 94%;(3) Age less than 2 hours
Exclusion Criteria
  • Intubated forany reasons at birth
  • Major congenital malformations or known complex congenital heart disease
  • No parental consent

NHFOV as Primary Support in Very Preterm Infants With RDS

Location Details


Please Choose a site



NHFOV as Primary Support in Very Preterm Infants With RDS

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations


Recruiting

China, Hunan

Hunan Provincial Maternal and Child Health Care Hospital

Changsha, Hunan, China,

Recruiting

China, Shandong

The Second Hospital of Shandong University

women, Shandong, China,

Recruiting

China, Yunnan

Qujing Maternity and child Healthcare Hospital

Q u fine, Yunnan, China,

Loading...